A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES • To evaluate the escalating single- and multiple-dose safety and tolerability of pregabalin, in comparison to placebo, in pediatric patients 1 month through 16 years of age with partial onset seizure...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE The primary objective of this Protocol is to assess the efficacy of PF-04447943, relative to placebo, on a performance-based measure of cognition in subjects with mild to moderate AD.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS •To estimate the objective response rate (ORR) of PF-03084014 when given as a single agent in the treatment of patients with advanced TNBC harboring genomic alterations in Notch receptors (NA+).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to test the safety and efficacy of PF-04449913 with azacitidine versus placebo with azacitidine in patients with Intermediate-2 or high risk myelodysplastic syndrome, acute myeloid leukemia with 20-30% blasts and multi-lineage dysplasia, or chronic myelomonocytic Primary Objectives for the Phase 1b (Safety Lead-In) •To assess the safety and tolerability of PF 04449913 when administered in combination with azacitidine in patients with previously untreated Inte...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A FOUR WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF VARENICLINE TARTRATE (CP-526,555) IN THE TREATMENT OF POST-HERPETIC NEURALGIA 1.To evaluate the analgesic efficacy of varenicline versus placebo in patients with postherpetic neuralgia (PHN) 2.To evaluate the safety and tolerability of varenicline versus placebo in patients w...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with one or two more Tyrosine Kinase Inhibitors Primary Objectives •To estimate the 1-year (Week 52) probability of cumulative Major Cytogenetic Response (MCyR) in CP Ph+ CML patients with 1 or 2 prior lines of TKI therapy. •To estimate the 1-yea...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A RANDOMISED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, MULTICENTRE STUDY IN ASYMPTOMATIC HIV-INFECTED PATIENTS TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERATION OF PF-00232798 - Investigate the effects of 10-day monotherapy of PF-00232798 on viral load response in asymptomatic HIV-infected patients and to the assess dose-response relationship. - Assess the pharmacokinetics,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in young adults to see if 3 doses of Mn B vaccine works Primary Objectives  To assess the immune response as measured by serum bactericidal assay using human complement (hSBA) performed with 4 primary MnB test strains, two expressing a LP2086 subfamily A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER To assess the efficacy of PD 0332334 in the treatment of GAD as measured by the change from Baseline in the HAM-A total score at Week 8. To assess the safety and tolerability of PD 0332334 in subjec...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021 - To assess long-term safety and tolerability of 20 mg BID of PF-02545920 in subjects with HD.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune